Recent developments in electroconvulsive therapy reveal that seizure duration is not a reliable prognostic outcome indicator. Propofol, although shortening seizure duration, does not affect outcome. Mivacurium represents an acceptable alternative to succinylcholine. Advances in monitoring and cardiovascular therapy allow even safe administration of electroconvulsive therapy in patients with cardiovascular disease, and esmolol and labetalol effectively reduce the cardiovascular response to electroconvulsive therapy.
展开▼
